OncoMatch/Clinical Trials/NCT07071714
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
Is NCT07071714 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SHR-8068 and Adebrelimab for colorectal cancer.
Treatment: SHR-8068 · Adebrelimab · Bevacizumab — The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic antitumor therapy
Part B: Systemic antitumor therapy was received 4 weeks before the start of the study.
Cannot have received: palliative radiotherapy
Part B: Palliative radiotherapy was completed within 14 days before the first dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify